Table 5.
Summary of risk factors of severe neonatal jaundice
| NICE | MaHTAS | QCG | INS | AAP | TPA | NPA | ISN | SAP | SSN | CPS | ChPS | |
| Maternal | ||||||||||||
| Blood group O | NA | + | + | + | + | NA | NA | NA | NA | NA | + | NA |
| Rhesus negative | + | + | + | + | + | NA | NA | NA | NA | NA | + | NA |
| Diabetes | NA | + | + | NA | + | NA | NA | NA | NA | NA | NA | NA |
| Neonatal | ||||||||||||
| G6PD deficiency | + | + | + | + | + | + | NA | NA | + | NA | + | + |
| Under 38 weeks | + | + | + | NA | + | + | NA | NA | + | NA | + | + |
| Exclusive breastfeeding | + | + | + | NA | + | NA | NA | NA | + | NA | + | + |
| Cephalhaematoma or bruises | – | + | + | NA | + | NA | NA | NA | + | NA | + | + |
| Sepsis | + | + | + | NA | + | + | NA | NA | + | NA | – | + |
| Sibling with severe hyperbilirubinemia | NA | + | NA | + | NA | NA | NA | NA | NA | NA | + | NA |
| Sibling with clinically significant jaundice requiring phototherapy | + | NA | + | NA | + | NA | NA | NA | NA | NA | NA | NA |
| Visible jaundice at younger than 24 hours | + | + | NA | + | + | NA | NA | NA | NA | NA | + | NA |
| Male | – | NA | + | NA | + | NA | NA | NA | NA | NA | + | NA |
AAP, American Academy of Pediatrics Subcommittee on Hyperbilirubinemia (America); ChPS, Chinese Pediatric Society, Chinese Medical Association (China); CPS, Canadian Pediatric Society, Fetus and Newborn Committee (Canada); G6PD, Glucose-6-phosphate dehydrogenase; INS, Israel Neonatal Society (Israel); ISN, Italian Society of Neonatology (Italy); MaHTAS, Malaysia Health Technology Assessment Section (Malaysia); NA, not available; NICE, National Institute for Health and Care Excellence (the UK); NPA, Norwegian Pediatric Association (Norway); QCG, Queensland Clinical Guidelines (Australia); SAP, Spanish Association of Pediatrics (Spain); SSN, Swiss Society of Neonatology (Swiss); TPA, Turkish Pediatric Association (Turkey).